Abstract of article: (My recommendations were implemented by the WHO and the EMA as standard practice in the treatment of ICU COVID-19 patients. The intensive care unit (ICU) treatment of patients presenting with severe COVID‐19, acute respiratory distress syndrome (ARDS) and severe inflammatory response is mostly being done using concomitant administration of tocilizumab, clinical trial drugs or hydroxychloroquine. This is accompanied by high levels of sedation using propofol infusions for at least 8-10 days (for purposes of mechanical ventilation). Long-term use of high doses of propofol in intubated COVID-19 patients may result in the development of “propofol infusion syndrome” (PRIS) which is characterized by hyperlipidemia and hypertriglyceridemia in the patient. In this letter, I present three validated cases showing the development of PRIS in intubated COVID-19 patients in ICUs (presenting with ARDS and renal failure) after long-term deep sedation with propofol. At present, there is a lack of validated clinical trial data on the complex associations of COVID-19 pharmacotherapy options and interactions with anaesthetic agents like propofol used for long-term sedation in ICU units. It is of vital importance for intensivists and anesthesiologists to monitor for the development of PRIS in intubated COVID-19 patients. This can help in avoiding associated adverse clinical outcomes and subsequent, fatal cardiac complications. The observations from the three cases highlight the link between aggravated levels of inflammatory markers and the incidence of PRIS. Intensivists and anesthesiologists must monitor for the development of PRIS in intubated COVID-19 patients, so as to provide timely discontinuation if necessary.